Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey
Sili et al., medRxiv, doi:10.1101/2020.10.09.20209775 (Preprint)
Sili et al., Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a.., medRxiv, doi:10.1101/2020.10.09.20209775 (Preprint)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the incidence of critical illness was lower than most studies. Authors note "whether HCQ administration lowered the rates of critical illness development is beyond the scope of this study." There is no comparison with a control group.
Sili et al., 11 Oct 2020, Turkey, preprint, 21 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey # Uluhan Sili* , Pinar Ay*, Ahmet Topuzoglu*, Huseyin Bilgin*, Elif Tukenmez Tigen, Buket Erturk Sengel, Dilek Yagci Caglayik, Baran Balcan, Derya Kocakaya, Sehnaz Olgun Yildizeli, Fethi Gul, Beliz Bilgili, Rabia Can Sarinoglu, Aysegul Karahasan Yagci, Lutfiye Mulazimoglu Durmusoglu, Emel Eryuksel, Zekaver Odabasi, Haner Direskeneli, Sait Karakurt, Ismail Cinel, Volkan Korten # * equal contribution # corresponding authors Uluhan Sili, Huseyin Bilgin, Elif Tukenmez Tigen, Buket Erturk Sengel, Dilek Yagci Caglayik, Lutfiye Mulazimoglu Durmusoglu, Zekaver Odabasi, Volkan Korten, Department of Infectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Istanbul, Turkey Pinar Ay, Ahmet Topuzoglu, Department of Public Health, Marmara University School of Medicine, Istanbul, Turkey Baran Balcan, Derya Kocakaya, Sehnaz Olgun Yildizeli, Emel Eryuksel, Sait Karakurt, Department of Pulmonary Medicine, Marmara University School of Medicine, Istanbul, Turkey Fethi Gul, Beliz Bilgili, Ismail Cinel, Department of Anesthesiology and Intensive Care, Marmara University School of Medicine, Istanbul, Turkey 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Rabia Can Sarinoglu, Aysegul Karahasan Yagci, Department of Medical Microbiology, Marmara University School of Medicine, Istanbul, Turkey Haner Direskeneli, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey Keywords: COVID-19, prospective cohort, critical illness, prognosis Running title: Critical illness development in COVID-19 Corresponding author: Uluhan Sili, MD, PhD Address: Department of Infectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Pendik Training and Research Hospital, 34896, Istanbul, Turkey Telephone: +90 505 746 5265 (mobile), +90 216 625 4693 (work) Fax: +90 216 625 4790 E-mail: uluhan@hotmail.com ; uluhan.sili@marmara.edu.tr Alternate corresponding author: Volkan Korten, MD Address: Department of Infectious Diseases and Clinical Microbiology, Marmara University School of Medicine, Pendik Training and Research Hospital, 34896, Istanbul, Turkey Telephone: +90 (532) 261 55 58 (mobile), +90 216 625 45 38 (work) Fax: +90 216 625 4790 E-mail: vkorten@gmail.com ; korten@marmara.edu.tr 2 medRxiv preprint doi: https://doi.org/10.1101/2020.10.09.20209775; this version posted October 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit